Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver

被引:438
作者
Park, SW
Moon, YA
Horton, JD
机构
[1] Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1074/jbc.M410077200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lipid homeostasis is transcriptionally regulated by three DNA-binding proteins, designated sterol regulatory element-binding protein (SREBP)-1a, - 1c, and -2. Oligonucleotide arrays hybridized with RNA made from livers of transgenic SREBP-1a, transgenic SREBP-2, and SREBP cleavage-activating protein knockout mice recently identified 33 genes regulated by SREBPs in liver, four of which had no known connection to lipid metabolism. One of the four genes was PCSK9, which encodes proprotein convertase subtilisin/kexin type 9a, a protein that belongs to the proteinase K subfamily of subtilases. Mutations in PCSK9 are associated with an autosomal dominant form of hypercholesterolemia. Here, we demonstrate that hepatic overexpression of either wild-type or mutant PCSK9 in mice results in hypercholesterolemia. The hypercholesterolemia is due to a post-transcriptional event causing a reduction in low density lipoprotein (LDL) receptor protein prior to the internalization and recycling of the receptor. Overexpression of PCSK9 in primary hepatocytes and in mice lacking the LDL receptor does not alter apolipoprotein B secretion. These data are consistent with PCSK9 affecting plasma LDL cholesterol levels by altering LDL receptor protein levels via a post-transcriptional mechanism.
引用
收藏
页码:50630 / 50638
页数:9
相关论文
共 46 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] *APPL BIOS, 2001, US B, V2
  • [3] The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
    Brown, MS
    Goldstein, JL
    [J]. CELL, 1997, 89 (03) : 331 - 340
  • [4] REGULATION OF ACTIVITY OF LOW-DENSITY LIPOPROTEIN RECEPTOR IN HUMAN FIBROBLASTS
    BROWN, MS
    GOLDSTEIN, JL
    [J]. CELL, 1975, 6 (03) : 307 - 316
  • [5] Transport-dependent proteolysis of SREBP: Relocation of Site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi
    DeBose-Boyd, RA
    Brown, MS
    Li, WP
    Nohturfft, A
    Goldstein, JL
    Espenshade, PJ
    [J]. CELL, 1999, 99 (07) : 703 - 712
  • [6] DIETSCHY JM, 1993, J LIPID RES, V34, P1637
  • [7] Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis
    Engelking, LJ
    Kuriyama, H
    Hammer, RE
    Horton, JD
    Brown, MS
    Goldstein, JL
    Liang, G
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (08) : 1168 - 1175
  • [8] Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins
    Espenshade, PJ
    Cheng, D
    Goldstein, JL
    Brown, MS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (32) : 22795 - 22804
  • [9] Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein
    Garcia, CK
    Wilund, K
    Arca, M
    Zuliani, G
    Fellin, R
    Maioli, M
    Calandra, S
    Bertolini, S
    Cossu, F
    Grishin, N
    Barnes, R
    Cohen, JC
    Hobbs, HH
    [J]. SCIENCE, 2001, 292 (5520) : 1394 - 1398
  • [10] LOW-DENSITY LIPOPROTEIN PATHWAY AND ITS RELATION TO ATHEROSCLEROSIS
    GOLDSTEIN, JL
    BROWN, MS
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1977, 46 : 897 - 930